Souza PMG, Carvalho BRD, Nakagawa HM, Rassi TRE, Barbosa ACP, Silva AA. Corifollitropin alfa compared to daily rFSH or HP-HMG in GnRH antagonist controlled ovarian stimulation protocol for patients undergoing assisted reproduction.
JBRA Assist Reprod 2017;
21:67-69. [PMID:
28609269 PMCID:
PMC5473695 DOI:
10.5935/1518-0557.20170017]
[Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
Objective
This study aimed to compare the outcomes of controlled ovarian stimulation
(COS) with corifollitropin alfa versus daily recombinant
follicle-stimulating hormone (rRFSH) or highly purified human menopausal
gonadotropin (HP-HMG) in patients undergoing in vitro
fertilization (IVF) cycles based on gonadotropin-releasing hormone (GnRH)
antagonist protocols. The primary endpoints were total number of oocytes and
mature oocytes.
Methods
This retrospective study looked into 132 controlled ovarian stimulation
cycles from IVF or oocyte cryopreservation performed in a private human
reproduction center between January 1 and December 31, 2014. Enrollment
criteria: women aged < 40 years submitted to COS with corifollitropin
alfa 100µg or 150µg (n = 26) and rFSH or HP-HMG in the first
seven days of treatment with daily doses of 150-225 IU (n = 106); all
subjects were on GnRH antagonist protocols.
Results
The groups had similar mean ages and duration of stimulation. The mean number
± standard deviation of total aspirated oocytes and MII oocytes was
11.9±10 and 10.3±7.9 in the corifollitropin alfa group, and
10.9±7.2 and 8.6±5.7 in the group on rFSH or HMG
(p>0.05). There were no significant differences in
fertilization (76.9% vs. 76.8%, p=1.0), biochemical
pregnancy (66.7% vs. 47.2%, p=0.1561) or embryo
implantation rates (68.7% vs. 50%, p=0.2588) between the
groups using corifollitropin alfa and rFSH or HMG, respectively.
Conclusions
Corifollitropin alfa seems to be as effective as rFSH or HP-HMG when used in
the first seven days of ovulation induction for patients undergoing assisted
reproduction in GnRH antagonist protocols.
Collapse